View Financial HealthPoxel 배당 및 자사주 매입배당 기준 점검 0/6Poxel 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026공시 • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France공시 • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.공시 • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.공시 • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025공시 • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.공시 • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon France공시 • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.공시 • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon France공시 • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PXXL.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PXXL.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Poxel 배당 수익률 vs 시장PXXL.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PXXL.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (PXXL.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PXXL.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PXXL.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PXXL.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PXXL.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 20:13종가2026/03/27 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Poxel S.A.는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason ButlerCitizens JMP Securities, LLCDavid SeynnaeveDegroof PetercamPeter WelfordJefferies LLC5명의 분석가 더 보기
공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026
공시 • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France
공시 • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.
공시 • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.
공시 • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.
공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025
공시 • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.
공시 • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon France
공시 • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.
공시 • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon France
공시 • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023